Price targets

Analyst ratings

3 analysts rated this company in the past 90 days. The average target price is €39.67, this is a change of +22.6% compared to the current price.

• September 8, 2025

  Jefferies maintains Dermapharm on 'Hold' - target 34 euros

  NEW YORK (dpa-AFX Analyser) - The analyst firm Jefferies has maintained its "Hold" rating for Dermapharm with a price target of €34. Management is confident about the earnings target, Fabian Piasta wrote on Monday after a meeting with the CFO. However, caution remains with regard to the low-revenue subsidiary Arkopharma./rob/ag/edh

  Publication of the original study: September 8, 2025 / 6:07 a.m. / Time zone not specified in the study

  First distribution of the original study: September 8, 2025 / 6:07 a.m. / Time zone not specified in the study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 27, 2025

  Jefferies downgrades Dermapharm to 'Hold' - target down to 34 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has lowered its price target for Dermapharm shares from €49 to €34 and downgraded the stock from "Buy" to "Hold." After the prolonged underperformance of shares of mid-cap European companies, the experts explore the opportunities in their analysis published Thursday. The German investment package and a possible ceasefire provide a good basis for a reassessment of growth sectors and cyclical companies. However, they expect slower growth for Dermapharm and lack price drivers./ag/ajx

  Publication of the original study: August 27, 2025 / 1:52 PM / ET

  First distribution of the original study: August 27, 2025 / 7:00 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 26, 2025

  Warburg Research maintains Dermapharm at 'Hold' - Target 41 euros

  HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its "Hold" rating for Dermapharm with a price target of €41. Margins are robust, but restructuring costs are weighing on the company, Christian Ehmann wrote on Tuesday after the company's figures were released./ag/ajx

  Publication of the original study: August 26, 2025 / 8:15 a.m. / CEST

  First distribution of the original study: Date not specified in study / Time not specified in study / CEST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 26, 2025

  Jefferies maintains Dermapharm at 'Buy' - target 49 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for Dermapharm with a price target of €49. Confirmed key figures and annual targets for the pharmaceutical manufacturer point to rising profits in the second half of the year, Fabian Piasta wrote on Tuesday after the company's results./rob/ag/edh

  Publication of the original study: August 26, 2025 / 2:09 a.m. / Time zone not specified in the study

  First distribution of the original study: August 26, 2025 / 2:09 a.m. / Time zone not specified in the study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 12, 2025

  Warburg Research maintains Dermapharm at 'Hold' - Target 41 euros

  HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has maintained its "Hold" rating for Dermapharm following preliminary half-year figures, with a price target of €41. The manufacturer of pharmaceuticals and other healthcare products performed steadily in the first half of the year, Christian Ehmann wrote in an initial assessment on Tuesday. Branded pharmaceuticals have shown strong organic growth, especially those for allergies./rob/bek/edh

  Publication of the original study: August 12, 2025 / 8:15 a.m. / Time zone not specified in study

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 17, 2025

  Warburg Research maintains Dermapharm at 'Hold' - Target 41 euros

  HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has maintained its "Hold" rating for Dermapharm with a price target of €41. The outlook for the manufacturer of dermatological and allergological pharmaceutical products is stable, wrote Christian Ehmann in a study released Tuesday. The company is well positioned internationally and operates with disciplined margins./rob/bek/he

  Publication of the original study: June 17, 2025 / 2:00 p.m. / Time zone not specified in the study. First distribution of the original study: Date not specified in the study / Time not specified in the study / Time zone not specified in the study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 10, 2025

  Warburg Research starts Dermapharm with 'Hold' - Target 41 euros

  HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has included Dermapharm in its rating with a "Hold" rating and a price target of €41. The vertically integrated specialty pharmaceutical platform is characterized by its structurally strong margins, wrote Christian Ehmann in a study published Tuesday. Dermapharm is strongly positioned in niche markets and a quality company in the volatile European pharmaceutical landscape. However, the share price already reflects all of this. The paper is "fairly valued."/rob/ck/ajx

  Publication of the original study: June 10, 2025 / 8:15 a.m. / CEST

  First distribution of the original study: Date not specified in the study / Time not specified in the study / CEST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 16, 2025

  Berenberg maintains Dermapharm at 'Buy' - target 44 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Dermapharm following its first-quarter results, with a price target of €44. The pharmaceutical manufacturer performed solidly and largely met market expectations, Gerhard Orgonas wrote in an assessment released on Monday. Overall, while there are few immediate price drivers, Dermapharm remains attractively valued as a defensive stock. In addition, further rapid debt reduction could open up new opportunities with regard to potential acquisitions./rob/la/ajx

  Publication of the original study: May 16, 2025 / 4:00 PM / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 15, 2025

  Jefferies maintains Dermapharm at 'Buy' - target 49 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for Dermapharm after the company's results, with a price target of €49. At first glance, the first quarter was a slower start to the year, Fabian Piasta wrote in a study released Thursday. However, he also pointed to challenging comparative figures from the previous year. The pharmaceutical company's objectives remain intact./rob/tih/edh

  Publication of the original study: May 15, 2025 / 2:14 AM / ET

  First distribution of the original study: May 15, 2025 / 2:14 AM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 4, 2025

  Berenberg lowers target for Dermapharm to 44 euros - 'Buy'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for Dermapharm from €50 to €44 following the final annual figures, but has left the rating at "Buy." Analyst Gerhard Orgonas wrote in a study published Monday that there are few immediate price drivers for the pharmaceutical manufacturer's shares. Nevertheless, the shares remain attractively valued./la/mis

  Publication of the original study: April 4, 2025 / 4:27 p.m. / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 4, 2024

  Berenberg maintains Dermapharm at 'Buy' - target 50 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained a "Buy" rating on Dermapharm with a price target of €50. The pharmaceutical manufacturer provided an overview of the key drivers of its current strong growth, wrote analyst Gerhard Orgonas in his commentary published Thursday following a meeting with CFO Christoph Dreibholz at the Berenberg investor conference. Dermapharm is currently not planning any acquisitions and is focusing on organic growth and debt reduction./gl/ag

  Publication of the original study: December 4, 2024 / 10:42 / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 27, 2024

  Jefferies maintains Dermapharm at 'Buy' - target 49 euros

  NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has maintained its rating for Dermapharm at "Buy" with a price target of EUR 49 at the investor event "German Equity Forum 2024". The pharmaceutical manufacturer's management confirmed its annual targets and signaled a strong October and a solid start to November, according to a commentary released Thursday./edh/ag

  Publication of the original study: November 27, 2024 / 4:00 PM / ET

  First distribution of the original study: November 27, 2024 / 7:00 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 14, 2024

  Berenberg lowers target for Dermapharm to 50 euros - 'Buy'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg lowered its price target for Dermapharm from €58 to €50 following quarterly figures, but maintained its "Buy" rating. The pharmaceutical manufacturer has returned to strong organic growth, analyst Gerhard Orgonas wrote in a study released Friday. He justified the lower price target with higher capital costs in his valuation approach./edh/ajx

  Publication of the original study: November 14, 2024 / 5:41 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 14, 2024

  Jefferies maintains Dermapharm at 'Buy' - target 49 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for Dermapharm after the company's earnings release, with a price target of €49. At first glance, the pharmaceutical company had a strong third quarter, wrote analyst Fabian Piasta in a report released Thursday. Sales and profit development exceeded expectations, and the outlook was confirmed.

  Publication of the original study: November 14, 2024 / 2:14 a.m. / ET

  First distribution of the original study: November 14, 2024 / 2:14 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 5, 2024

  Jefferies maintains Dermapharm at 'Buy' - target 49 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its rating for Dermapharm at "Buy" with a price target of €49. Analyst Fabian Piasta wrote this on Thursday after discussions with the company's Chief Financial Officer and Chief Partner and Business Relations Officer (CCO)./ag/gl

  Publication of the original study: September 5, 2024 / 1:35 p.m. / ET. First distribution of the original study: September 5, 2024 / 7:00 p.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 2, 2024

  Jefferies lowers target for Dermapharm to 49 euros - 'Buy'

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has lowered its price target for Dermapharm from €51 to €49, but maintained its "Buy" rating. In a study released Tuesday, analyst Martin Comtesse examines investment opportunities in small and medium-sized European companies, whose valuations—unlike those of large companies—are still as cheap as ever. While a broad-based recovery is still a long way off, interest rates in the eurozone have already begun to reverse the trend. Meanwhile, he paints a mixed picture for the pharmaceutical manufacturer Dermapharm. Even if the comparable figures from the previous year are easier to achieve in the second half of the year and product launches are pending, the profit contributions from the subsidiary Arkopharma are likely to be lower than expected./tih/ck

  Publication of the original study: September 2, 2024 / 7:15 p.m. / ET

  First distribution of the original study: September 2, 2024 / 7:16 p.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 28, 2024

  Berenberg maintains Dermapharm at 'Buy' - target 58 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Dermapharm after the company's earnings release, with a price target of €58. The second quarter marks the pharmaceutical company's return to growth, wrote analyst Gerhard Orgonas in a report published Thursday. The solid cash flow should serve to reduce debt. The valuation is extremely favorable./mf/gl

  Publication of the original study: August 28, 2024 / 5:18 PM / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 27, 2024

  Jefferies maintains Dermapharm at 'Buy' - target 51 euros

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its "Buy" rating for Dermapharm with a price target of €51. The final figures for the second quarter offer no surprises following the preliminary results presented in mid-August, analyst Fabian Piasta wrote in a study published Tuesday. In his view, the decisive factor is an improvement in the economic situation in France, which will favor the market launch of new products planned for the second half of the year./lfi/ngu

  Publication of the original study: August 27, 2024 / 2:17 a.m. / ET

  First distribution of the original study: August 27, 2024 / 2:17 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.